NCT/Study#
NCT04176198 /
BBI-TP-3654-102
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
DISEASE GROUP:
Leukemia
current phase:
Phase I
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
